Related references
Note: Only part of the references are listed.Cariprazine in the treatment of Bipolar Disorder: A systematic review and meta-analysis
Jairo Vinicius Pinto et al.
BIPOLAR DISORDERS (2020)
Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies
Roger S. McIntyre et al.
CNS SPECTRUMS (2020)
Mixed mood states: Baffled, bewildered, befuddled and bemused
Stephen M. Stahl et al.
BIPOLAR DISORDERS (2019)
Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone
Filippo Corponi et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2019)
Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine
Bela Kiss et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials
Roger S. McIntyre et al.
JOURNAL OF AFFECTIVE DISORDERS (2019)
Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study
Willie Earley et al.
AMERICAN JOURNAL OF PSYCHIATRY (2019)
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder
Heinz Grunze et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2018)
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder
Lakshmi N. Yatham et al.
BIPOLAR DISORDERS (2018)
The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study
Terence A. Ketter et al.
JOURNAL OF AFFECTIVE DISORDERS (2018)
Cariprazine in Bipolar Depression and Mania: State of the Art
Marianna Mazza et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2018)
Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial
Maurizio Fava et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2018)
Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
Leslie Citrome
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2018)
Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials
Filippo Corponi et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2017)
Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model
Vanja Duric et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2017)
Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial
Gyorgy Nemeth et al.
LANCET (2017)
Guidelines for the recognition and management of mixed depression
Stephen M. Stahl et al.
CNS SPECTRUMS (2017)
An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression
Suresh Durgam et al.
AMERICAN JOURNAL OF PSYCHIATRY (2016)
Mechanism of action of cariprazine
Stephen M. Stahl
CNS SPECTRUMS (2016)
The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders
Domenico De Berardis et al.
CURRENT PHARMACEUTICAL DESIGN (2016)
Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants: A Randomized, Double-Blind, Placebo-Controlled Study in Adult Patients With Major Depressive Disorder
Suresh Durgam et al.
JOURNAL OF CLINICAL PSYCHIATRY (2016)
Cariprazine in the treatment of acute mania in bipolar trial I disorder: A double-blind, placebo-controlled, Phase III
Gary S. Sachs et al.
JOURNAL OF AFFECTIVE DISORDERS (2015)
The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial
Suresh Durgam et al.
BIPOLAR DISORDERS (2015)
Efficacy and Safety of Low- and High-Dose Cariprazine in Acute and Mixed Mania Associated With Bipolar I Disorder: A Double-Blind, Placebo-Controlled Study
Joseph R. Calabrese et al.
JOURNAL OF CLINICAL PSYCHIATRY (2015)
A proposal for an updated neuropsychopharmacological nomenclature
Joseph Zohar et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2014)
Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression
Mariusz Papp et al.
BEHAVIOURAL PHARMACOLOGY (2014)
Dopamine D3 receptor as a new pharmacological target for the treatment of depression
Gian Marco Leggio et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability
Leslie Citrome
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse
Ross Zimnisky et al.
PSYCHOPHARMACOLOGY (2013)
Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents
Istvan Gyertyan et al.
NEUROCHEMISTRY INTERNATIONAL (2011)
Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
Bela Kiss et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Share Paper
